N-phenylbenzo[4,5]thieno[3,2-d]pyrimidin-4-amine | 1414524-13-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并嘧啶酮衍生物
• 英文名称: N-phenylbenzo[4,5]thieno[3,2-d]pyrimidin-4-amine
• 英文别名: N-phenylbenzothieno[3,2-d]pyrimidin-4-amine；N-phenyl-[1]benzothiolo[3,2-d]pyrimidin-4-amine
• CAS: 1414524-13-2
• 化学式: C₁₆H₁₁N₃S
• 分子量: 277.349
• InChiKey: LTGQZQQOZBAZJZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-硝基苯甲腈 在 2-氰基乙硫醇 、 potassium hydroxide 作用下， 以 水 、 溶剂黄146 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.75h， 生成 N-phenylbenzo[4,5]thieno[3,2-d]pyrimidin-4-amine
  参考文献：
  名称：

  N-芳基苯并[b]呋喃[3,2-d]嘧啶-4-胺的高效新合成及其苯并[b]噻吩并[3,2-d]嘧啶-4-胺的类似物，通过微波辅助重铬酸钾重排

  摘要：

  可以快速有效地访问N-芳基苯并[ b ]呋喃[3,2 - d ]嘧啶-4-胺类库（1）及其新型苯并[ b ]噻吩并[3,2 - d ]嘧啶-4-胺类库首次研究了类似物（2）。通过苯并[ b ]呋喃和苯并[ b ]噻吩前体与N，N的反应获得的N '-（2-氰芳基）-N，N-二甲基甲亚胺通过微波加速缩合和合适的苯胺的Dimroth重排获得标题化合物-二甲基甲酰胺二甲基乙缩醛。这项工作还证明，控制良好的参数可以舒适地使用微波技术，既安全又有益于环境。本文获得的某些产品表现出有趣的体外抗增殖作用。

  DOI：

  10.1002/jhet.1716

文献信息

• Synthesis and biological evaluation of N-arylbenzo[b]thieno[3,2-d]pyrimidin-4-amines and their pyrido and pyrazino analogues as Ser/Thr kinase inhibitors
  作者：Yvonnick Loidreau、Pascal Marchand、Carole Dubouilh-Benard、Marie-Renée Nourrisson、Muriel Duflos、Olivier Lozach、Nadège Loaëc、Laurent Meijer、Thierry Besson

  DOI：10.1016/j.ejmech.2012.10.006

  日期：2012.12

  A useful and rapid access to libraries of N-arylbenzo[b]thieno[3,2-d]pyrimidin-4-amines and their pyrido and pyrazino analogues was designed and optimized for the first time via microwave-accelerated condensation and Dimroth rearrangement of the starting anilines with N′-(2-cyanoaryl)-N,N-dimethylformimidamides obtained by reaction of thiophene precursors with dimethylformamide dimethylacetal. The

  通过微波加速的缩合反应和Dimroth重排设计并首次优化和优化了N-芳基苯并[ b ]噻吩并[3,2 - d ]嘧啶-4-胺及其吡啶基和吡嗪类似物的库的快速访问方法。通过噻吩前体与二甲基甲酰胺二甲基乙缩醛反应获得的N '-（2-氰基芳基）-N，N-二甲基甲亚胺与起始苯胺。估计了最终产物对五种蛋白激酶（CDK5 / p25，CK1δ/ɛ，GSK3α/β，DYRK1A和CLK1）的抑制力。N-芳基吡啶并[3'，2'：4,5]噻吩并[3,2 - d ]嘧啶-4-胺系列化合物（事实证明，图4a – j）对于开发新的CK1和CLK1激酶药理抑制剂具有特别的希望。
• Synthesis and evaluation of apoptosis induction of thienopyrimidine compounds on KRAS and BRAF mutated colorectal cancer cell lines
  作者：Stéphane Pédeboscq、Denis Gravier、Françoise Casadebaig、Geneviève Hou、Arnaud Gissot、Christophe Rey、François Ichas、Francesca De Giorgi、Lydia Lartigue、Jean-Paul Pometan

  DOI：10.1016/j.bmc.2012.09.034

  日期：2012.11

  Monoclonal antibodies (MoAb) and tyrosine kinase inhibitors (TKI) targeting the EGFR (Epidermal Growth Factor Receptor) pathways are currently used in colorectal cancer treatment. Despite the improvement of median overall survival, resistance is observed notably due to KRAS and BRAF gene mutations. We synthesized four series of thienopyrimidines whose scaffold is structurally close to TKI used in clinical practice. We evaluated apoptosis induced by these compounds using flow cytometry on KRAS and BRAF mutated cell lines. Our results confirm that the mutated cell lines (HCT116 and HT29) are more resistant to apoptosis than the non-mutated cell line (Hela). Interestingly, among the 13 compounds tested, three of them (5b, 6b and 6d) and gefitinib exhibited a noteworthy pro-apoptotic effect, especially on mutated cell lines with an IC50 value between 70 and 110 mu M. These three compounds seem particularly attractive for the development of novel treatments for colorectal cancer patients harboring EGFR pathway mutations. (C) 2012 Elsevier Ltd. All rights reserved.